AU747416B2 - Pharmaceutical composition for the treatment of rheumatic syndromes containing sulfur, mustard seeds and a copper salt - Google Patents

Pharmaceutical composition for the treatment of rheumatic syndromes containing sulfur, mustard seeds and a copper salt Download PDF

Info

Publication number
AU747416B2
AU747416B2 AU19616/00A AU1961600A AU747416B2 AU 747416 B2 AU747416 B2 AU 747416B2 AU 19616/00 A AU19616/00 A AU 19616/00A AU 1961600 A AU1961600 A AU 1961600A AU 747416 B2 AU747416 B2 AU 747416B2
Authority
AU
Australia
Prior art keywords
paralysis
pharmaceutical preparation
weight
medicament
following
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU19616/00A
Other versions
AU1961600A (en
Inventor
Norbert Gschwend
Norbert A. Gschwend
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU1961600A publication Critical patent/AU1961600A/en
Application granted granted Critical
Publication of AU747416B2 publication Critical patent/AU747416B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

WO 00/43021 PCT/CH00/00027 PHARMACEUTICAL PREPARATION,, CONTAINING SULFUR, MUSTARD SEEDS AND A CUPRIC SALT, FOR TREATING RHEUMATIC SYNDROMES This invention relates to a pharmaceutical preparation offering significantly improved properties in the treatment of rheumatic syndromes, especially rheumatism, arthritis, sciatica and/or gout, a cutaneous form of administration of a pharmaceutical preparation, a foot powder, as well as a method for producing a pharmaceutical preparation and, respectively, a foot powder.
Existing literature describes various active agents used in treating rheumatic and rheumatoid syndromes. For example, in a special supplement to "Zeitschrift for Arztliche Fortbildung" (journal for advanced medical training), vol. XIII, 15 Nov 1959, No. 150, pages 798 to 802, titled "the practical physician", H. Seliger states that it is especially colloidal sulfur that has proved effective in treating rheumatism, arthritis and sciatia, among others. Beneficial additives mentioned by him include camphor and camomile flowers. H. Seliger makes special reference to a pharmaceutical preparation marketed by the N. Gschwend company of Herisau which contains the three active ingredients mentioned together with talcum as the carrier substance.
The monograph D. IT07.10.4 referred to in the bibliography of the IKS Monthly of 12/1994 describes mustard seed and camomile flowers as pharmaceutically effective substances in the cutaneous treatment of arthritis and rheumatic disorders.
Then there are a number of sulfur-containing preparations, indicated for "rheumatism", in the form of bath oils and additives with names such as "Soufrol", "Sulfur-Oil-Bath" and "Leukona Sulfomoor-Bath".
This invention is aimed at introducing another pharmaceutical preparation with good and/or improved properties for the treatment of rheumatic sydromes.
According to a first aspect, the present invention consists in a pharmaceutical preparation for treating rheumatic syndromes containing at least the following active agents: sulfur, mustard seed as well as a cupric salt.
According to a second aspect, the present invention consists in a cutaneous form of administration employing a pharmaceutical preparation according to the first aspect.
According to a third aspect, the present invention consists in a cutaneous 1o administration according to the second aspect wherein it is in the form of a foot powder suitable for application on the sole of the foot.
According to a fourth aspect, the present invention consists in a process for producing a pharmaceutical preparation according to the first aspect wherein, in a first step, talc and sulfur are mixed in powder form, followed by a second step in which a 1 5 small amount of a so-called "catalytic powder" is added, said catalytic powder being a pulverulent mixture composed of talc, mustard seed and a cupric salt.
According to a fifth aspect, the present invention consists in application of the Sprocess according to the fourth aspect for producing a foot powder for treating rheumatic syndromes.
*o 20 According to a sixth aspect, the present invention consists in use of the pharmaceutical preparation according to the first aspect for treating one of the following disorders or ailments: sciatica, muscular rheumatism, arthritis, phlebitis (inflammation of a vein), excessively high or low blood pressure, paralysis deformans (a degenerative, chronic, not acutely inflammatory disease of a joint), paralysis post myelitis (inflammation of the spinal cord), poliomyelitis (polio), paralysis cerabralis (brain-related paralysis), paralysis post nephritis vel uraemia (paralysis following a kidney infection or poisoning of the urinary tract), paralysis postlaesion cause alicuia mechanica (paralysis following injuries/lesions after surgical procedures, a fall, impact eczema, and/or X-ray induced bums.
According to a seventh aspect, the present invention consists in use of sulfur, mustard seed and cupric salt in the manufacture of a medicament for treating rheumatic syndromes.
[R:\LIBW]46250.doc:RMC 2a According to an eighth aspect, the present invention consists in use of sulfur, mustard seed and cupric salt in the manufacture of a medicament for treating one of the following disorders or ailments: sciatica, muscular rheumatism, arthritis, phlebitis (inflammation of a vein), excessively high or low blood pressure, paralysis deformans (a degenerative, chronic, not acutely inflammatory disease of a joint), paralysis post myelitis (inflammation of the spinal cord), poliomyelitis (polio), paralysis cerabralis (brain-related paralysis), paralysis post nephritis vel uraemia (paralysis following a kidney infection or poisoning of the urinary tract), paralysis postlaesion cause alicuia mechanica (paralysis following injuries/lesions after surgical procedures, a fall, impact), eczema, and/or X-ray induced •bums.
According to a ninth aspect, the present invention consists in a method of treating o rheumatic syndromes comprising administering to a patient in need of such treatment, a pharmaceutical preparation according to the first aspect.
S 15 According to a tenth aspect, the present invention consists in a method of treating one of the following disorders or ailments: sciatica, muscular rheumatism, arthritis, phlebitis (inflammation of a vein), excessively high or low blood pressure, paralysis deformans (a degenerative, chronic, not i'":acutely inflammatory disease of a joint), paralysis post myelitis (inflammation of the 20 spinal cord), poliomyelitis (polio), paralysis cerabralis (brain-related paralysis), paralysis post nephritis vel uraemia (paralysis following a kidney infection or poisoning of the "urinary tract), paralysis postlaesion cause alicuia mechanica (paralysis following injuries/lesions after surgical procedures, a fall, impact), eczema, and/or X-ray induced bums, comprising administering to a patient in need of such treatment, a pharmaceutical preparation according to the first asepct.
According to a eleventh aspect, the present invention consists in a pharmaceutical preparation according to the first aspect when used for treating rheumatic syndromes.
According to a twelfth aspect, the present invention consists in a pharmaceutical preparation according to the first aspect when used for treating one of the following disorders or ailments: sciatica, muscular rheumatism, arthritis, phlebitis (inflammation of a vein), .,excessively high or low blood pressure, paralysis deformans (a degenerative, chronic, not I'N- itely inflammatory disease of a joint), paralysis post myelitis (inflammation of the [R:\LIBW]46250.doc:RMC 2b spinal cord), poliomyelitis (polio), paralysis cerabralis (brain-related paralysis), paralysis post nephritis vel uraemia (paralysis following a kidney infection or poisoning of the urinary tract), paralysis postlaesion cause alicuia mechanica (paralysis following injuries/lesions after surgical procedures, a fall, impact), eczema, and/or X-ray induced bums.
Typically the rheumatic syndrome is rheumatism, arthritis, sciatica and/or gout.
Typically the cupric salt is copper sulphate. Suitably the preparation additionally comprises camomile, suitably camomile flowers, camphor and/or potassium iodate.
Suitably the preparation comprises talc as a carrier. Suitably the preparation is in powder io form. In one embodiment the preparation comprises volume concentrations of the following: .30 50% by weight sulfur, preferably 30 40% by weight; o 0 10% by weight camomile, preferably 5 -10% by weight; 0 25% by weight camphor, preferably 15 -25% by weight; Is 0.5 2.5% by weight mustard seed, preferably 1 1.5% by weight; 0.05 0.3% by weight copper sulphate, preferably 0.1 0.15% by weight; 0 0.15% by weight potassium iodate, preferably 0.05 0.1% by weight; talc making up the remainder up to 100% by weight.
Suitably in the process, in the first step, camphor and/or camomile in the form of 20 camomile flowers are optionally added and in the second step, potassium iodate is further S: added to the "catalytic powder". Suitably in the first step, the components are first mixed in powder form in a mixer such as a 4-way mixer, following which the components to be added in the second step are screened and added in powder form to, and thoroughly blended with, the mixture of the first step.
The active agents contained in the pharmaceutical preparation according to this invention for the treatment of rheumatic syndromes and especially rheumatism, arthritis, sciatica and/or gout include at least sulfur, mustard seed and a cupric salt.
The invention also covers a cutaneous form of administration, for the treatment of rheumatic syndromes, of a pharmaceutical preparation per this invention. The cutaneous form of administration preferably employs a fine-particle foot powder specially prepared for application on the sole of the foot.
The preferred fine foot powder is sprinkled into shoes, socks, stockings or liners whereupon the active ingredients are absorbed into the blood stream through the sole of RA' the foot. This is a unique form of applying a rheumatism antidote and constitutes a rticular aspect directly associated with the special combination of the individual active [R:\LIBW]46250.doc:RMC 2c ingredients as proposed by this invention. The functional mechanism is based on the fact that, as the substance makes contact with live and keratinous tissue (that being the sole of the foot), a number of chemical transformations take place, aided by the effect of natural aspiration, even natural perspiration, leading to corresponding reactions in two *oo**o *ooo* o** **g [R:\LIBW]46250.doc: RMC -3ways, i.e. by way of both the blood stream and the nerve tissue. As an obvious prerequisite, the active agents must be adequately resorbed by the skin, which is assured by the particular combination of active ingredients per this invention. By virtue of the above-mentioned transdermal absorption the organism will only take up exactly the amount of active substances that it needs.
Key components of the compounds introduced by this invention are such active ingredients, present in trace amounts only, as cupric salt which preferably consists of copper sulfate, and potassium iodate, to both of which a certain catalytic effect is attributed. Correspondingly, these two substances, in conjunction with talc as the carrier substance, form a so-called "catalytic powder" which is added in minuscule amounts to the other active agents including in particular sulfur and mustard seed.
The process of producing the pharmaceutical preparation begins with a first step in which talc is mixed with sulfur as the active agent plus, as an option, camphor and camomile flowers. For the blending operation the active ingredients are prepowderized and, of course, the talc, or talcum, constituting the carrier substance, is pulverulent on its part.
As the second step of the process, a minuscule amount of the above-mentioned so-called "catalytic powder" is added to the mixture. The catalytic powder again consists of talc as well as mustard seed, the cupric salt preferably in the form of copper sulfate, and, as an option, potassium iodate.
The advantage of adding potassium iodate derives in particular from the fact that it stabilizes the pharmaceutical preparation for use in hot or tropical regions. The talcum carrier substance is known to be less than absolutely stable or suitable for use in tropical or hot zones, which makes the addition of potassium iodate necessary or advisable.
The following explains this invention in more detail with the aid of the production-process examples given below and with reference to a sample composition.
As mentioned above, the production follows a bipartite process, i.e. the pharmaceutical preparation according to this invention is produced in two steps, dividing the composition into two parts.
Part 1: Sulfur: Camomile: Camphor: Talcum (balance): Approx. 30 50 by weight, preferably 30 40 by weight; 0 -10 preferably 5 -10 0 25 preferably 15 25 20 65 Total, Part 1: 85 95 Part 2: Mustard seed: Copper sulfate: Potassium iodate: Talcum: 0.5 2.5 preferably 1 1.5 0.05 0.3 preferably 0.1 0.15 0 0.15 preferably 0.05 0.1 3-13% Total, Part 2: 5-15% The quantities expressed in percent by weight relate to the total weight of the preparation composed of Part 1 and Part 2.
For producing the preparation, the first step is to mix Part 1 for which purpose the individual components are ground into ultrafine powder and screened, then blended with talc in a mixer, for instance a so-called 4-way mixer, for about 15 minutes.
Part 2 is produced by first grinding copper sulfate and, if applicable, potassium iodate in a mortar using a pestle until a homogeneous powder is obtained. These components are then sifted, together with talc and mustard seed, for instance through a screen and are then added to and blended with the mixture of Part 1. This can again be performed in a 4-way mixer, in this case for about 20 minutes.
Of course, the above quantities are indicated as examples only, subject to variation and modification depending on the application i.e. form of administration and on the ailment to be treated. Likewise, the mixtures can naturally be produced by methods deviating from that described above. It is important, however, that especially when a foot powder is produced, the different components making up the foot powder be thoroughly mixed -6so as to result in a fine powder mixture.
It is also possible to administer the preparation in the form of a cream, paste or the like, containing the pharmaceutical preparation for instance as an ultrafine powder together with carrier substances and other additives.
Apart from the indications first above mentioned, the pharmaceutical preparations according to this invention have also been found to be suitable for application in the case of the following disorders or ailments: Sciatia, muscular rheumatism, arthritis, phlebitis (inflammation of a vein), excessively high or low blood pressure, paralysis deformans, paralysis post myelitis, poliomyelitis, paralysis cerebralis, paralysis post nephritis vel uraemia, paralysis postlaesion cause alicuia mechanica, eczema, and x-ray burns.

Claims (64)

1. A pharmaceutical preparation for treating rheumatic syndromes containing at least the following active agents: sulfur, mustard seed as well as a cupric salt.
2. A pharmaceutical preparation according to claim 1 arthritis, sciatica and/or gout.
3. A pharmaceutical preparation according to claim 1 salt employed is copper sulfate. for treating rheumatism, or 2, wherein the cupric S S5S* S
4. A pharmaceutical preparation according additionally containing camomile.
A pharmaceutical preparation according to camomile flowers.
6. A pharmaceutical preparation according containing talc as a carrier substance. 15is
7. A pharmaceutical preparation according additionally containing camphor.
8. A pharmaceutical preparation according additionally containing potassium iodate. to any one of claims 1 to 3, claim 4, wherein the camomile is to any one of claims to any one of claims to any one of claims 1 to 1 to 6, 1 to 7,
9. A pharmaceutical preparation according to any one of claims 1 to 7, wherein the preparation is produced in powder form.
A pharmaceutical preparation according to any one of claims 1 to 9, having the following volume concentrations of the various components: sulfur: 30 50% by weight; camomile: 0 10% by weight; camphor: 0 25% by weight; mustard seed: 0.5 2.5% by weight; copper sulphate: 0.05 0.3% by weight; potassium iodate:0 0.15% by weight; talc making up the remainder up to 100% by weight.
11. A pharmaceutical preparation according to claim 10 containing 30 40% by weight sulfur.
12. A pharmaceutical preparation according to claim 10 or 11 containing 5 Sby weight camomile.
P, t13. A pharmaceutical 'preparation according to any one of claims 10 to 12 containing 15 25% by weight camphor. [R:\LIBW]4625O doc:RMC 8
14. A pharmaceutical preparation according to any one of claims 10 to 13 containing 1 1.5% by weight mustard seed.
A pharmaceutical preparation according to any one of claims 10 to 14 containing 0.1 0.15% by weight copper sulfate.
16. A pharmaceutical preparation according to any one of claims 10 to containing 0.05 0.1% by weight potassium iodate.
17. A cutaneous form of administration employing a pharmaceutical preparation according to any one of claims 1 to 16.
18. A cutaneous administration according to claim 17 wherein it is in the form of a foot powder suitable for application on the sole of the foot.
19. A process for producing a pharmaceutical preparation according to any one of claims 1 to 16 wherein, in a first step, talc and sulfur are mixed in powder form, followed by a second step in which a small amount of a so-called "catalytic powder" is added, said catalytic powder being a pulverulent mixture composed of talc, mustard seed 15 and a cupric salt.
A process according to claim 19, wherein the cupric salt is copper sulfate.
21. A process according to claims 19 or 20, wherein in the first step, camphor and/or camomile in the form of camomile flowers are optionally added and in the second step, potassium iodate is further added to the "catalytic powder". S. 20
22. A process according to any one of claims 19 to 21 wherein in the first step, #ooo the components are first mixed in powder form in a mixer following which the •o components to be added in the second step are screened and added in powder form to, and thoroughly blended with, the mixture of the first step.
23. A process according to claim 22 wherein the mixer is a 4-way mixer.
24. Application of the process according to any one of claims 19 to 22 for producing a foot powder for treating rheumatic syndromes.
Application according to claim 24 wherein the rheumatic syndrome is rheumatism, arthritis, sciatica and/or gout.
26. Use of the pharmaceutical preparation according to any one of claims 1 to 16 for treating one of the following disorders or ailments: sciatica, muscular rheumatism, arthritis, phlebitis (inflammation of a vein), excessively high or low blood pressure, paralysis deformans (a degenerative, chronic, not acutely inflammatory disease of a joint), paralysis post myelitis (inflammation of the R,4,spinal cord), poliomyelitis (polio), paralysis cerabralis (brain-related paralysis), paralysis "post~ nephritis vel uraemia (paralysis following a kidney infection or poisoning of the 0 [R:\LBW]6250doc: RMC [R:\LIBW]46250.doc: RMC urinary tract), paralysis postlaesion cause alicuia mechanica (paralysis following injuries/lesions after surgical procedures, a fall, impact eczema, and/or X-ray induced bums.
27. Use of sulfur, mustard seed and cupric salt in the manufacture of a medicament for treating rheumatic syndromes.
28. Use according to claim 27 wherein the rheumatic syndrome is rheumatism, arthritis, sciatica and/or gout.
29. Use according to claim 27 or 28 wherein the cupric salt is copper sulphate.
Use according to any one of claims 27 to 29 wherein the medicament additionally comprises camomile.
31. Use according to claim 30 wherein the camomile is camomile flowers.
32. Use according to any one of claims 27 to 31 comprising talc as a carrier.
33. Use according to any one of claims 27 to 32 wherein the medicament additionally comprises camphor. Is 15
34. Use according to any one of claims 27 to 33 wherein the medicament additionally comprises potassium iodate.
35. Use according to any one of claims 27 to 33 wherein the medicament is in powder form.
I36. Use according to any one of claims 27 to 35 wherein the medicament comprises volume concentrations of the following: 50% by weight sulfur; 0 10% by weight camomile; 0 25% by weight camphor; 2.5% by weight mustard seed; 0.05 0.3% by weight copper sulphate; 0 0.15% by weight potassium iodate, talc making up the remainder up to 100% by weight.
37. Use according claim 36 wherein sulfur is contained in the medicament in an amount of 30 40% by weight.
38. Use according to claims 36 or 37 wherein camomile is contained in the medicament in an amount of 5 10% by weight.
39. Use according to any one of claims 36 to 38 wherein camphor is contained in the medicament in an amount of 15 25% by weight.
Use according to any one of claims 36 to 39 wherein mustard seed is ontained in the medicament in an amount of 1 1.5% by weight. [R:\LIBW]46250.doc:RMC
41. Use according to any one of claims 36 to 40 wherein copper sulfate is contained in the medicament in an amount of 0.1 0.15% by weight.
42. Use according to any one of claims 36 to 41 wherein potassium iodate is contained in the medicament in an amount of 0.05 by weight.
43. Use according to any one of claims 36 to 42 wherein the medicament is for cutaneous administration.
44. Use according to any one of claims 36 to 43 wherein the medicament is for cutaneous administration is the form of a foot powder for application on the sole of the foot.
45. Use of sulfur, mustard seed and cupric salt in the manufacture of a medicament for treating one of the following disorders or ailments: isciatica, muscular rheumatism, arthritis, phlebitis (inflammation of a vein), excessively high or low blood pressure, paralysis deformans (a degenerative, chronic, not acutely inflammatory disease of a joint), paralysis post myelitis (inflammation of the S 15 spinal cord), poliomyelitis (polio), paralysis cerabralis (brain-related paralysis), paralysis post nephritis vel uraemia (paralysis following a kidney infection or poisoning of the urinary tract), paralysis postlaesion cause alicuia mechanica (paralysis following injuries/lesions after surgical procedures, a fall, impact), eczema, and/or X-ray induced bums. 0.0.
46. A method of treating rheumatic syndromes comprising administering to a patient in need of such treatment, a pharmaceutical preparation according to any one of o* claims 1 to 16.
47. A method according to claim 46 wherein the administering is by cutaneous administration.
48. A method according to claim 46 or 47 wherein the administering is by cutaneous administration wherein the preparation is in the form of a foot powder and is applied to the sole of the foot.
49. A method according to any one of claims 46 to 48 wherein the rheumatic syndrome is rheumatism, arthritis, sciatica and/or gout.
50. A method of treating one of the following disorders or ailments: sciatica, muscular rheumatism, arthritis, phlebitis (inflammation of a vein), excessively high or low blood pressure, paralysis deformans (a degenerative, chronic, not acutely inflammatory disease of a joint); paralysis post myelitis (inflammation of the &spinal cord), poliomyelitis (polio), paralysis cerabralis (brain-related paralysis), paralysis rpost nephritis vel uraemia (paralysis following a kidney infection or poisoning of the [R:\LIBW]46250.doc: RMC 11 urinary tract), paralysis postlaesion cause alicuia mechanica (paralysis following injuries/lesions after surgical procedures, a fall, impact), eczema, and/or X-ray induced bums, comprising administering to a patient in need of such treatment, a pharmaceutical preparation according to any one of claims 1 to 16.
51. A pharmaceutical preparation according to any one of claims 1 to 16 when used for treating rheumatic syndromes.
52. A pharmaceutical preparation when used according to claim 51 wherein the pharmaceutical preparation is administered by cutaneous administration.
53. A pharmaceutical preparation when used according to claim 51 or 52 wherein the pharmaceutical preparation is administered by cutaneous administration wherein the preparation is in the form ofa foot powder and is applied to the sole of the foot.
54. A pharmaceutical preparation when used according to any one of claims 51 to 53 wherein the rheumatic syndrome is rheumatism, arthritis, sciatica and/or gout. S 15
55. A pharmaceutical preparation according to any one of claims 1 to 16 when used for treating one of the following disorders or ailments: sciatica, muscular rheumatism, arthritis, phlebitis (inflammation of a vein), excessively high or low blood pressure, paralysis deformans (a degenerative, chronic, not S.acutely inflammatory disease of a joint), paralysis post myelitis (inflammation of the spinal cord), poliomyelitis (polio), paralysis cerabralis (brain-related paralysis), paralysis post nephritis vel uraemia (paralysis following a kidney infection or poisoning of the urinary tract), paralysis postlaesion cause alicuia mechanica (paralysis following injuries/lesions after surgical procedures, a fall, impact), eczema, and/or X-ray induced bums.
56. A pharmaceutical preparation for treating rheumatic syndromes, substantially as hereinbefore described with reference to any one of the examples.
57. A process for preparing a pharmaceutical preparation for treating rheumatic syndromes, said process being substantially as hereinbefore described with the reference to any one of the examples.
58. A pharmaceutical preparation prepared by the process of any one of claims 19 to 22 or 57.
59. A method of treating rheumatic syndromes comprising administering to a RA .patient in need of such treatment, a pharmaceutical preparation according to claim 56 or S 35
60. A method of treating one of the following disorders or ailments: [R:\LIBW]46250.doc:RMC 12 sciatica, muscular rheumatism, arthritis, phlebitis (inflammation of a vein), excessively high or low blood pressure, paralysis deformans (a degenerative, chronic, not acutely inflammatory disease of a joint), paralysis post myelitis (inflammation of the spinal cord), poliomyelitis (polio), paralysis cerabralis (brain-related paralysis), paralysis post nephritis vel uraemia (paralysis following a kidney infection or poisoning of the urinary tract), paralysis postlaesion cause alicuia mechanica (paralysis following injuries/lesions after surgical procedures, a fall, impact eczema, and/or X-ray induced bums, comprising administering to a patient in need of such treatment, a pharmaceutical preparation according to claim 56 or 58. I, 1
61. A pharmaceutical preparation according to claim 56 or 58 when used for treating rheumatic syndromes.
62. A pharmaceutical preparation according to claim 56 or 58 when used for i: trreating one of the following disorders or ailments: 15 sciatica, muscular rheumatism, arthritis, phlebitis (inflammation of a vein), excessively high or low blood pressure, paralysis deformans (a degenerative, chronic, not acutely inflammatory disease of a joint), paralysis post myelitis (inflammation of the spinal cord), poliomyelitis (polio), paralysis cerabralis (brain-related paralysis), paralysis post nephritis vel uraemia (paralysis following a kidney infection or poisoning of the 20 urinary tract), paralysis postlaesion cause alicuia mechanica (paralysis following g. injuries/lesions after surgical procedures, a fall, impact eczema, and/or X-ray induced bums.
63. Use of sulfur, mustard seed and cupric salt in the manufacture of a medicament for treating rheumatic syndromes, said medicament being substantially as hereinbefore described with reference to any one of the examples.
64. Use of sulfur, mustard seed and cupric salt in the manufacture of a medicament for treating one of the following disorders or ailments: sciatica, muscular rheumatism, arthritis, phlebitis (inflammation of a vein), excessively high or low blood pressure, paralysis deformans (a degenerative, chronic, not acutely inflammatory disease of a joint), paralysis post myelitis (inflammation of the spinal cord), poliomyelitis (polio), paralysis cerabralis (brain-related paralysis), paralysis post nephritis vel uraemia (paralysis following a kidney infection or poisoning of the urinary tract), paralysis postlaesion cause alicuia mechanica (paralysis following q injuries/lesions after surgical procedures, a fall, impact), eczema, and/or X-ray induced (R:\LIBW]46250.doc:RMC I 13 bums, said medicament being substantially as hereinbefore described with reference to any one of the examples. Cutaneous form of administration using a pharmaceutical preparation according to claim 56 or 58. Dated 7 March, 2002 Norbert A. Gschwend Norbert Gschwend Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON *0 0 S0. 0 Oo. 00 0, 9065 [R:\LIBW]46250.doc: RMC
AU19616/00A 1999-01-20 2000-01-19 Pharmaceutical composition for the treatment of rheumatic syndromes containing sulfur, mustard seeds and a copper salt Ceased AU747416B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99100923A EP0983766A1 (en) 1999-01-20 1999-01-20 A pharmaceutical composition for the treatment of rheumatoid disorders comprising sulphur, mustard seeds and a copper salt
EP99100923 1999-01-20
PCT/CH2000/000027 WO2000043021A1 (en) 1999-01-20 2000-01-19 Pharmaceutical composition for the treatment of rheumatic syndromes containing sulfur, mustard seeds and a copper salt

Publications (2)

Publication Number Publication Date
AU1961600A AU1961600A (en) 2000-08-07
AU747416B2 true AU747416B2 (en) 2002-05-16

Family

ID=8237372

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19616/00A Ceased AU747416B2 (en) 1999-01-20 2000-01-19 Pharmaceutical composition for the treatment of rheumatic syndromes containing sulfur, mustard seeds and a copper salt

Country Status (10)

Country Link
EP (1) EP0983766A1 (en)
JP (1) JP2002535280A (en)
KR (1) KR20010113657A (en)
CN (1) CN1337882A (en)
AU (1) AU747416B2 (en)
BR (1) BR0007641A (en)
CA (1) CA2358474A1 (en)
IL (1) IL144439A0 (en)
NO (1) NO20013555L (en)
WO (1) WO2000043021A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101462090B1 (en) * 2006-06-02 2014-11-17 내츄럴 엠에이 인코포레이티드 Use of micron-sized sulphur for the prevention and treatment of pathogenic disorders in humans and animals
CN104225112B (en) * 2013-06-13 2017-12-22 陈卫衡 A kind of Chinese medicine composition for treating Osteoarthritis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE8128911U1 (en) * 1981-10-02 1982-06-16 Energy-Pak Europe Ltd., 9490 Vaduz Magnetic plaster
CH660971A5 (en) * 1983-07-07 1987-06-30 Schwab F A & Co Therapeutic composition
DE3433076A1 (en) * 1984-09-08 1986-03-20 Alfred Dipl.-Biochem. 7400 Tübingen Gärtner Process for the isolation and use of copper metallothioneins for antirheumatic therapy
CN1032622C (en) * 1993-01-19 1996-08-28 王来运 Medical liquid for relaxing tendons and joints
CN1099970A (en) * 1993-09-11 1995-03-15 宋建祥 Health clothing and articles with Chinese medicines and producing method thereof
CN1130074A (en) * 1995-03-01 1996-09-04 李凤欣 External application medicine for chronic rheumatic hyperosteogeny
GB2315674B (en) * 1996-08-01 2000-06-21 Richard John Cleeve Mammalian foodstuff
CN1191729A (en) * 1997-02-20 1998-09-02 李国荣 Pain paster
CN1164410A (en) * 1997-04-22 1997-11-12 高贵 External use preparation for curing phlebitis
CN1049353C (en) * 1997-07-30 2000-02-16 张巨文 Chinese medicinal preparation for curing rheumatism and rheumatoid disease and its prepn. method
CN1057001C (en) * 1997-09-10 2000-10-04 沈春楼 Chinese medicine capsule for rheumatoid disease

Also Published As

Publication number Publication date
NO20013555L (en) 2001-09-10
KR20010113657A (en) 2001-12-28
EP0983766A1 (en) 2000-03-08
NO20013555D0 (en) 2001-07-18
IL144439A0 (en) 2002-05-23
CN1337882A (en) 2002-02-27
WO2000043021A1 (en) 2000-07-27
CA2358474A1 (en) 2000-07-27
BR0007641A (en) 2001-10-16
JP2002535280A (en) 2002-10-22
AU1961600A (en) 2000-08-07

Similar Documents

Publication Publication Date Title
KR100329249B1 (en) Nasal administration composition
EP1827405A2 (en) Capsaicinoid gel formulation and uses thereof
CN103239520B (en) Moslemic ointment for treating osteoarthritis and preparation method of moslemic ointment
AU723812B2 (en) Medicinal preparation and a method of medicinal action on human organism
JP4865792B2 (en) Local anesthetic effect enhancement / time extender
AU747416B2 (en) Pharmaceutical composition for the treatment of rheumatic syndromes containing sulfur, mustard seeds and a copper salt
CA1169774A (en) Medication having penetration through cutaneous surfaces into articular and muscular areas
US20070099882A1 (en) Methods and compositions for prolonged alleviation of articular joint pain
RU2268052C2 (en) Agent for treatment of inflammatory and degenerative joint disease (variants), method for treatment of inflammatory and degenerative joint disease (variants) and device for delivery of medicinal agent to damaged site
CN101904958B (en) Oral medicinal composition for treating fracture
TWI262080B (en) Process for reacting alkaloids and use of the reaction products
CN101977609B (en) Pharmaceutical composition for preventing and treating bone resorption of different etiology
Low et al. An engineered dual function peptide to repair fractured bones
KR100347883B1 (en) New pharmaceutical composition of gel preparation containing local anaesthetic agents
JP3534793B2 (en) Glycyrrhizinate rectal formulation
RU2097057C1 (en) Composition of ointment showing analgetic and local irritating action with heat effect
CN108404094A (en) A kind of thin network analgesic antiphlogistic bee venom application conditioning cream
CN1031689C (en) Medicine for treating lumbar vertebra hyperosteogeny diseases
RU2203040C1 (en) Medicinal composition for physical therapy and cosmetology
WO2008136012A1 (en) Oral medicinal preparations
KR100584214B1 (en) The method of manufacturing potentiator using oyster shell powder
CN105853968A (en) Ginger and folium artemisiae argyi scraping agent and preparation method thereof
RU2352339C2 (en) Method of arthralgia treatment
CN101176790B (en) Percutaneous absorption fortifier
JPH0320218A (en) Corn therapeutic agent

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 14, NO 44, PAGE(S) 7916-7918 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN PLEASE DELETE ALL REFERENCE TO APPLICATION NO. 19616/00

FGA Letters patent sealed or granted (standard patent)